论文部分内容阅读
目的:评价替罗非班与美托洛尔联用对急性心肌梗死(acute myocardial infarction,AMI)患者心功能复常及其对血清Hs-CRP水平的影响。方法:选取2013年9月—2016年10月间收治的AMI患者78例,采用随机数字表法将其分为对照组和观察组,每组39例;对照组患者给予美托洛尔治疗,观察组患者在对照组基础加用替罗非班治疗;评价两组患者治疗后的总有效率和治疗前后两组患者左室射血分数(LVEF)、左室舒张末径(LVDEd)及超敏C-反应蛋白(Hs-CRP)测得值的变化情况。结果:观察组患者治疗后的总有效率为94.87%高于对照组为76.92%(P<0.05);和治疗后观察组患者LVEF、LVDEd测得值优于对照组(P<0.05),Hs-CRP测得值低于对照组(P<0.05)。结论:替罗非班与美托洛尔联用于AMI患者,降低了血清hs-CRP水平,改善心功能的疗效较为显著。
Objective: To evaluate the effects of tirofiban and metoprolol on cardiac function and serum Hs-CRP levels in patients with acute myocardial infarction (AMI). Methods: Seventy-eight AMI patients were selected from September 2013 to October 2016. The patients were divided into control group and observation group with 39 cases in each group by random number table method. Patients in the control group were treated with metoprolol, The patients in the observation group were treated with tirofiban on the basis of the control group. The total effective rate and the left ventricular ejection fraction (LVEF), left ventricular diastolic diameter (LVDEd) C-reactive protein (Hs-CRP) measured value changes. Results: After treatment, the total effective rate of the observation group was 94.87%, which was significantly higher than that of the control group (76.92%, P <0.05). The LVEF and LVDEd values of the observation group were better than those of the control group (P <0.05) -CRP measured values lower than the control group (P <0.05). Conclusion: Tirofiban combined with metoprolol in patients with AMI, reduce serum hs-CRP levels, the effect of improving cardiac function is more significant.